{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T11:49:52Z","timestamp":1788349792283,"version":"build-2803163510"},"reference-count":118,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2016,6,11]],"date-time":"2016-06-11T00:00:00Z","timestamp":1465603200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CNS Drugs"],"published-print":{"date-parts":[[2016,7]]},"DOI":"10.1007\/s40263-016-0349-0","type":"journal-article","created":{"date-parts":[[2016,6,11]],"date-time":"2016-06-11T04:37:33Z","timestamp":1465619853000},"page":"603-628","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":72,"title":["The Safety of Atomoxetine for the Treatment of Children and Adolescents with Attention-Deficit\/Hyperactivity Disorder: A Comprehensive Review of Over a Decade of Research"],"prefix":"10.1007","volume":"30","author":[{"given":"Victoria A.","family":"Reed","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan K.","family":"Buitelaar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ernie","family":"Anand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen Ann","family":"Day","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tam\u00e1s","family":"Treuer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Himanshu P.","family":"Upadhyaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David R.","family":"Coghill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ludmila A.","family":"Kryzhanovskaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola C.","family":"Savill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,6,11]]},"reference":[{"key":"349_CR1","first-page":"104","volume":"2","author":"SV Faraone","year":"2003","unstructured":"Faraone SV, Sergeant J, Gillberg C, Biederman J. The worldwide prevalence of ADHD: is it an American condition? World Psychiatry. 2003;2:104\u201313.","journal-title":"World Psychiatry."},{"key":"349_CR2","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1007\/s13311-012-0135-8","volume":"9","author":"EG Willcutt","year":"2012","unstructured":"Willcutt EG. The prevalence of DSM-IV attention-deficit\/hyperactivity disorder: a meta-analytic review. Neurotherapeutics. 2012;9:490\u20139.","journal-title":"Neurotherapeutics."},{"key":"349_CR3","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1176\/ajp.2007.164.6.942","volume":"164","author":"G Polanczyk","year":"2007","unstructured":"Polanczyk G, de Lima MS, Horta BL, et al. The worldwide prevalence of ADHD: a systematic review and metaregression analysis. Am J Psychiatry. 2007;164:942\u20138.","journal-title":"Am J Psychiatry"},{"key":"349_CR4","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1093\/ije\/dyt261","volume":"43","author":"GV Polanczyk","year":"2014","unstructured":"Polanczyk GV, Willcutt EG, Salum GA, et al. ADHD prevalence estimates across three decades: an updated systematic review and meta-regression analysis. Int J Epidemiol. 2014;43:434\u201342.","journal-title":"Int J Epidemiol"},{"key":"349_CR5","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1097\/00004583-200011000-00017","volume":"39","author":"P Rasmussen","year":"2000","unstructured":"Rasmussen P, Gillberg C. Natural outcome of ADHD with developmental coordination disorder at age 22\u00a0years: a controlled, longitudinal, community-based study. J Am Acad Child Adolesc Psychiatry. 2000;39:1424\u201331.","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"349_CR6","first-page":"12","volume":"8","author":"J Biederman","year":"2006","unstructured":"Biederman J, Faraone SV. The effects of attention-deficit\/hyperactivity disorder on employment and household income. MedGenMed. 2006;8:12.","journal-title":"MedGenMed."},{"key":"349_CR7","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1016\/j.jaac.2012.07.008","volume":"51","author":"JA Doshi","year":"2012","unstructured":"Doshi JA, Hodgkins P, Kahle J, et al. Economic impact of childhood and adult attention-deficit\/hyperactivity disorder in the United States. J Am Acad Child Adolesc Psychiatry. 2012;51:990\u20131002.","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"349_CR8","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1192\/bjp.bp.109.066274","volume":"196","author":"K Langley","year":"2010","unstructured":"Langley K, Fowler T, Ford T, et al. Adolescent clinical outcomes for young people with attention-deficit hyperactivity disorder. Br J Psychiatry. 2010;196:235\u201340.","journal-title":"Br J Psychiatry"},{"key":"349_CR9","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1002\/cbm.1860","volume":"23","author":"S Dalsgaard","year":"2013","unstructured":"Dalsgaard S, Mortensen PB, Frydenberg M, Thomsen PH. Long-term criminal outcome of children with attention deficit hyperactivity disorder. Crim Behav Ment Health. 2013;23:86\u201398.","journal-title":"Crim Behav Ment Health."},{"key":"349_CR10","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1016\/S0140-6736(14)61684-6","volume":"385","author":"S Dalsgaard","year":"2015","unstructured":"Dalsgaard S, \u00d8stergaard SD, Leckman JF, et al. Mortality in children, adolescents, and adults with attention deficit hyperactivity disorder: a nationwide cohort study. Lancet. 2015;385:2190\u20136.","journal-title":"Lancet"},{"key":"349_CR11","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1542\/peds.2012-2354","volume":"131","author":"WJ Barbaresi","year":"2013","unstructured":"Barbaresi WJ, Colligan RC, Weaver AL, et al. Mortality, ADHD, and psychosocial adversity in adults with childhood ADHD: a prospective study. Pediatrics. 2013;131:637\u201344.","journal-title":"Pediatrics"},{"key":"349_CR12","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1007\/s40263-014-0224-9","volume":"29","author":"NC Savill","year":"2015","unstructured":"Savill NC, Buitelaar JK, Anand E, et al. The efficacy of atomoxetine for the treatment of children and adolescents with attention-deficit\/hyperactivity disorder: a comprehensive review of over a decade of clinical research. CNS Drugs. 2015;29:131\u201351.","journal-title":"CNS Drugs."},{"key":"349_CR13","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1177\/0269881113519509","volume":"28","author":"B Bolea-Alama\u00f1ac","year":"2014","unstructured":"Bolea-Alama\u00f1ac B, Nutt DJ, Adamou M, British Association for Psychopharmacology, et al. Evidence-based guidelines for the pharmacological management of attention deficit hyperactivity disorder: update on recommendations from the British Association for Psychopharmacology. J Psychopharmacol. 2014;28:179\u2013203.","journal-title":"J Psychopharmacol."},{"key":"349_CR14","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1177\/1087054710379737","volume":"15","author":"PL Hazell","year":"2011","unstructured":"Hazell PL, Kohn MR, Dickson R, et al. Core ADHD symptom improvement with atomoxetine versus methylphenidate: a direct comparison meta-analysis. J Atten Disord. 2011;15:674\u201383.","journal-title":"J Atten Disord."},{"key":"349_CR15","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1186\/1471-244X-11-176","volume":"11","author":"R Hanwella","year":"2011","unstructured":"Hanwella R, Senanayake M, de Silva V. Comparative efficacy and acceptability of methylphenidate and atomoxetine in treatment of attention deficit hyperactivity disorder in children and adolescents: a meta-analysis. BMC Psychiatry. 2011;11:176.","journal-title":"BMC Psychiatry."},{"key":"349_CR16","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1097\/CHI.0b013e31819c55b2","volume":"48","author":"JH Newcorn","year":"2009","unstructured":"Newcorn JH, Sutton VK, Weiss MD, Sumner CR. Clinical responses to atomoxetine in attention-deficit\/hyperactivity disorder: the Integrated Data Exploratory Analysis (IDEA) study. J Am Acad Child Adolesc Psychiatry. 2009;48:511\u20138.","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"349_CR17","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1097\/FAD.0b013e3283383a63","volume":"260","author":"P Panei","year":"2010","unstructured":"Panei P, Arcieri R, Bonati M, et al. Safety of psychotropic drug prescribed for attention-deficit\/hyperactivity disorder in Italy. Adverse Drug React Bull. 2010;260:999\u20131002.","journal-title":"Adverse Drug React Bull."},{"key":"349_CR18","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1089\/cap.2012.0003","volume":"22","author":"S Ruggiero","year":"2012","unstructured":"Ruggiero S, Rafaniello C, Bravaccio C, et al. Safety of attention-deficit\/hyperactivity disorder medications in children: an intensive pharmacosurveillance monitoring study. J Child Adolesc Psychopharmacol. 2012;22:415\u201322.","journal-title":"J Child Adolesc Psychopharmacol."},{"key":"349_CR19","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1007\/s00228-011-1050-3","volume":"67","author":"A Didoni","year":"2011","unstructured":"Didoni A, Sequi M, Panei P, et al. One-year prospective follow-up of pharmacological treatment in children with attention-deficit\/hyperactivity disorder. Eur J Clin Pharmacol. 2011;67:1061\u20137.","journal-title":"Eur J Clin Pharmacol"},{"key":"349_CR20","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1089\/cap.2012.0014","volume":"22","author":"R Arcieri","year":"2012","unstructured":"Arcieri R, Germinario EA, Bonati M, et al. Cardiovascular measures in children and adolescents with attention-deficit\/hyperactivity disorder who are new users of methylphenidate and atomoxetine. J Child Adolesc Psychopharmacol. 2012;22:423\u201331.","journal-title":"J Child Adolesc Psychopharmacol."},{"key":"349_CR21","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1089\/cap.2012.0086","volume":"23","author":"EA Germinario","year":"2013","unstructured":"Germinario EA, Arcieri R, Bonati M, et al. Attention-deficit\/hyperactivity disorder drugs and growth: an Italian prospective observational study. J Child Adolesc Psychopharmacol. 2013;23:440\u20137.","journal-title":"J Child Adolesc Psychopharmacol."},{"key":"349_CR22","unstructured":"STRATTERA\u00ae. Summary of product characteristics. Eli Lilly & Co. http:\/\/www.medicines.org.uk\/emc\/history\/14482 Accessed 1 Dec 2015."},{"key":"349_CR23","unstructured":"STRATTERA\u00ae. Full prescribing information. Eli Lilly & Co. http:\/\/pi.lilly.com\/us\/strattera-pi.pdf Accessed 1 Dec 2015."},{"key":"349_CR24","unstructured":"STRATTERA\u00ae. Full prescribing information. Eli Lilly & Co. http:\/\/www.accessdata.fda.gov\/scripts\/cder\/drugsatfda\/index.cfm?fuseaction=Search.Label_ApprovalHistory#apphist Accessed 1 Dec 2015."},{"key":"349_CR25","doi-asserted-by":"crossref","first-page":"g3769","DOI":"10.1136\/bmj.g3769","volume":"348","author":"Q Chen","year":"2014","unstructured":"Chen Q, Sj\u00f6lander A, Runeson B, et al. Drug treatment for attention-deficit\/hyperactivity disorder and suicidal behaviour: register based study. BMJ. 2014;348:g3769.","journal-title":"BMJ"},{"key":"349_CR26","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1089\/cap.2014.0005","volume":"24","author":"ME Bangs","year":"2014","unstructured":"Bangs ME, Wietecha LA, Wang S, et al. Meta-analysis of suicide-related behavior or ideation in child, adolescent, and adult patients treated with atomoxetine. J Child Adolesc Psychopharmacol. 2014;24:426\u201334.","journal-title":"J Child Adolesc Psychopharmacol."},{"key":"349_CR27","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.jaac.2013.11.005","volume":"53","author":"S Schwartz","year":"2014","unstructured":"Schwartz S, Correll CU. Efficacy and safety of atomoxetine in children and adolescents with attention-deficit\/hyperactivity disorder: results from a comprehensive meta-analysis and metaregression. J Am Acad Child Adolesc Psychiatry. 2014;53:174\u201387.","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"349_CR28","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1089\/cap.2007.0066","volume":"17","author":"ME Bangs","year":"2007","unstructured":"Atomoxetine ADHD and Comorbid MDD Study Group, Bangs ME, Emslie GJ, et al. Efficacy and safety of atomoxetine in adolescents with attention-deficit\/hyperactivity disorder and major depression. J Child Adolesc Psychopharmacol. 2007;17:407\u201320.","journal-title":"J Child Adolesc Psychopharmacol."},{"key":"349_CR29","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1097\/chi.0b013e31815d88b2","volume":"47","author":"ME Bangs","year":"2008","unstructured":"Bangs ME, Tauscher-Wisniewski S, Polzer J, et al. Meta-analysis of suicide-related behavior events in patients treated with atomoxetine. J Am Acad Child Adolesc Psychiatry. 2008;47:209\u201318.","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"349_CR30","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1097\/CHI.0b013e318193060e","volume":"48","author":"C Donnelly","year":"2009","unstructured":"Donnelly C, Bangs M, Trzepacz P, et al. Safety and tolerability of atomoxetine over 3 to 4\u00a0years in children and adolescents with ADHD. J Am Acad Child Adolesc Psychiatry. 2009;48:176\u201385.","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"349_CR31","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1111\/j.1556-4029.2005.00021.x","volume":"51","author":"D Garside","year":"2006","unstructured":"Garside D, Ropero-Miller JD, Riemer EC. Postmortem tissue distribution of atomoxetine following fatal and nonfatal doses: three case reports. J Forensic Sci. 2006;51:179\u201382.","journal-title":"J Forensic Sci"},{"key":"349_CR32","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1089\/cap.2006.0132","volume":"18","author":"JM Tamayo","year":"2008","unstructured":"Tamayo JM, Pumariega A, Rothe EM, et al. Latino versus Caucasian response to atomoxetine in attention-deficit\/hyperactivity disorder. J Child Adolesc Psychopharmacol. 2008;18:44\u201353.","journal-title":"J Child Adolesc Psychopharmacol."},{"issue":"1","key":"349_CR33","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/1753-2000-2-11","volume":"2","author":"PM Wehmeier","year":"2008","unstructured":"Wehmeier PM, Schacht A, Lehmann M, et al. Emotional well-being in children and adolescents treated with atomoxetine for attention-deficit\/hyperactivity disorder: findings from a patient, parent and physician perspective using items from the pediatric adverse event rating scale (PAERS). Child Adolesc Psychiatry Ment Health. 2008;2(1):11.","journal-title":"Child Adolesc Psychiatry Ment Health."},{"key":"349_CR34","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1111\/j.1440-1754.2008.01389.x","volume":"44","author":"GA Paxton","year":"2008","unstructured":"Paxton GA, Cranswick NE. Acute suicidality after commencing atomoxetine. J Paediatr Child Health. 2008;44:596\u20138.","journal-title":"J Paediatr Child Health"},{"key":"349_CR35","unstructured":"Kilincaslan A, Mutluer T, Pasabeyoglu B, et al. Treatment of children with autism spectrum disorders and co-existing attention deficit hyperactivity disorder, with atomoxetine: a retrospective study. In: 5th international congress on psychopharmacology and international symposium on child and adolescent psychopharmacology: Turkey; 30 Oct\u20133 Nov 2013."},{"key":"349_CR36","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/1753-2000-7-19","volume":"7","author":"CJ Bushe","year":"2013","unstructured":"Bushe CJ, Savill NC. Suicide related events and attention deficit hyperactivity disorder treatments in children and adolescents: a meta-analysis of atomoxetine and methylphenidate comparator clinical trials. Child Adolesc Psychiatry Ment Health. 2013;7:19.","journal-title":"Child Adolesc Psychiatry Ment Health."},{"key":"349_CR37","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.2165\/11317630-000000000-00000","volume":"32","author":"S McCarthy","year":"2009","unstructured":"McCarthy S, Cranswick N, Potts L, et al. Mortality associated with attention-deficit hyperactivity disorder (ADHD) drug treatment: a retrospective cohort study of children, adolescents and young adults using the general practice research database. Drug Saf. 2009;32:1089\u201396.","journal-title":"Drug Saf"},{"key":"349_CR38","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/j.biopsych.2006.05.044","volume":"61","author":"J Polzer","year":"2007","unstructured":"Polzer J, Bangs ME, Zhang S, et al. Meta-analysis of aggression or hostility events in randomized, controlled clinical trials of atomoxetine for ADHD. Biol Psychiatry. 2007;61:713\u20139.","journal-title":"Biol Psychiatry"},{"key":"349_CR39","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1089\/cap.2009.0030","volume":"19","author":"K Chang","year":"2009","unstructured":"Chang K, Nayar D, Howe M, et al. Atomoxetine as an adjunct therapy in the treatment of co-morbid attention-deficit\/hyperactivity disorder in children and adolescents with bipolar I or II disorder. J Child Adolesc Psychopharmacol. 2009;19:547\u201351.","journal-title":"J Child Adolesc Psychopharmacol."},{"key":"349_CR40","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1089\/cap.2005.15.996","volume":"15","author":"M Hah","year":"2005","unstructured":"Hah M, Chang K. Atomoxetine for the treatment of attention-deficit\/hyperactivity disorder in children and adolescents with bipolar disorders. J Child Adolesc Psychopharmacol. 2005;15:996\u20131004.","journal-title":"J Child Adolesc Psychopharmacol."},{"key":"349_CR41","unstructured":"Aydemir H, Oztop DB, Uytun MC, et al. Is it ADHD or bipolar disorders? A case report. In: 5th international congress on psychopharmacology and international symposium on child and adolescent psychopharmacology: Turkey; 30 Oct\u20133 Nov 2013."},{"key":"349_CR42","unstructured":"Guney E, Uneri OS. Atomoxetine induced hypomania-like symptoms in a pre-adolescent patient. In: 5th international congress on psychopharmacology and international symposium on child and adolescent psychopharmacology: Turkey; 30 Oct\u20133 Nov 2013."},{"key":"349_CR43","doi-asserted-by":"crossref","first-page":"A185","DOI":"10.1016\/j.jval.2011.02.1025","volume":"14","author":"S Bhattacharjee","year":"2011","unstructured":"Bhattacharjee S, Chen H, Bhatara V, et al. Is stimulant or atomoxetine utilization associated with neurological adverse events in children with attention-deficit\/hyperactivity disorder (ADHD)? A retrospective analysis of propensity score matched data. Value Health. 2011;14:A185.","journal-title":"Value Health."},{"key":"349_CR44","first-page":"208","volume":"19","author":"I Dumitru","year":"2012","unstructured":"Dumitru I, Salan A. Treating children with epilepsy and comorbid attention-deficit\/hyperactivity disorder (ADHD). Eur J Neurol. 2012;19:208.","journal-title":"Eur J Neurol"},{"key":"349_CR45","doi-asserted-by":"crossref","first-page":"123","DOI":"10.2174\/157488608784529233","volume":"3","author":"AT McAfee","year":"2008","unstructured":"McAfee AT, Holdridge KC, Johannes CB, et al. The effect of pharmacotherapy for attention deficit hyperactivity disorder on risk of seizures in pediatric patients as assessed in an insurance claims database. Curr Drug Saf. 2008;3:123\u201331.","journal-title":"Curr Drug Saf."},{"key":"349_CR46","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1002\/pds.3390","volume":"22","author":"AT McAfee","year":"2013","unstructured":"McAfee AT, Landon J, Jones M, et al. A cohort study of the risk of seizures in a pediatric population treated with atomoxetine or stimulant medications. Pharmacoepidemiol Drug Saf. 2013;22:386\u201393.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"349_CR47","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1111\/j.1469-8749.2007.00498.x","volume":"49","author":"JF Wernicke","year":"2007","unstructured":"Wernicke JF, Holdridge KC, Jin L, et al. Seizure risk in patients with attention-deficit-hyperactivity disorder treated with atomoxetine. Dev Med Child Neurol. 2007;49:498\u2013502.","journal-title":"Dev Med Child Neurol"},{"key":"349_CR48","doi-asserted-by":"crossref","first-page":"345","DOI":"10.2165\/00002018-200831040-00008","volume":"31","author":"ME Bangs","year":"2008","unstructured":"Bangs ME, Jin L, Zhang S, et al. Hepatic events associated with atomoxetine treatment for attention-deficit hyperactivity disorder. Drug Saf. 2008;31:345\u201354.","journal-title":"Drug Saf"},{"key":"349_CR49","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/j.jpeds.2006.01.035","volume":"148","author":"JR Lim","year":"2006","unstructured":"Lim JR, Faught PR, Chalasani NP, et al. Severe liver injury after initiating therapy with atomoxetine in two children. J Pediatr. 2006;148:831\u20134.","journal-title":"J Pediatr"},{"key":"349_CR50","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1080\/15563650600795644","volume":"45","author":"SD Stojanovski","year":"2007","unstructured":"Stojanovski SD, Casavant MJ, Mousa HM, et al. Atomoxetine-induced hepatitis in a child. Clin Toxicol (Phila). 2007;45:51\u20135.","journal-title":"Clin Toxicol (Phila)."},{"key":"349_CR51","first-page":"S204","volume":"20","author":"OS Uneri","year":"2011","unstructured":"Uneri OS, Copur M, Tanidir C, et al. Liver enzymes levels during atomoxetine treatment in children and adolescents. Eur Child Adolesc Psychiatry. 2011;20:S204.","journal-title":"Eur Child Adolesc Psychiatry"},{"key":"349_CR52","first-page":"22","volume":"26","author":"OS Uneri","year":"2013","unstructured":"Uneri OS, Copur M, Tanidir C, et al. Liver enzymes and bilirubin levels during atomoxetine treatment in children and adolescents. D\u00fc\u015f\u00fcnen Adam. 2013;26:22\u20137.","journal-title":"D\u00fc\u015f\u00fcnen Adam."},{"key":"349_CR53","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1212\/01.wnl.0000188869.58300.a7","volume":"65","author":"AJ Allen","year":"2005","unstructured":"Allen AJ, Kurlan RM, Gilbert DL, et al. Atomoxetine treatment in children and adolescents with ADHD and comorbid tic disorders. Neurology. 2005;65:1941\u20139.","journal-title":"Neurology."},{"key":"349_CR54","doi-asserted-by":"crossref","first-page":"S429","DOI":"10.1016\/S0924-977X(12)70674-0","volume":"22","author":"A Camporeale","year":"2012","unstructured":"Camporeale A, Beasley C, Tanaka Y, et al. Changes in blood pressure and heart rate associated with atomoxetine treatment in attention-deficit\/hyperactivity disorder. Eur Neuropsychopharmacol. 2012;22:S429\u201330.","journal-title":"Eur Neuropsychopharmacol"},{"key":"349_CR55","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1089\/cap.2012.0027","volume":"23","author":"E Cardo","year":"2013","unstructured":"Cardo E, Porsdal V, Quail D, et al. Fast vs. slow switching from stimulants to atomoxetine in children and adolescents with attention-deficit\/hyperactivity disorder. J Child Adolesc Psychopharmacol. 2013;23:252\u201361.","journal-title":"J Child Adolesc Psychopharmacol."},{"key":"349_CR56","doi-asserted-by":"publisher","unstructured":"Carlson GA, Dunn D, Kelsey D, et al. A pilot study for augmenting atomoxetine with methylphenidate: safety of concomitant therapy in children with attention-deficit\/hyperactivity disorder. Child Adolesc Psychiatry Ment Health. 2007;1(10). doi: 10.1186\/1753-2000-1-10 .","DOI":"10.1186\/1753-2000-1-10"},{"key":"349_CR57","first-page":"26","volume":"33","author":"R Escobar","year":"2005","unstructured":"Escobar R, Soutullo C, San Sebasti\u00e1n J, et al. Atomoxetine safety and efficacy in children with attention deficit\/hyperactivity disorder (ADHD): initial phase of 10-week treatment in a relapse prevention study with a Spanish sample [in Spanish]. Actas Esp Psiquiatr. 2005;33:26\u201332.","journal-title":"Actas Esp Psiquiatr."},{"key":"349_CR58","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1089\/cap.2008.0126","volume":"19","author":"P Hammerness","year":"2009","unstructured":"Hammerness P, Georgiopoulos A, Doyle RL, et al. An open study of adjunct OROS-methylphenidate in children who are atomoxetine partial responders: II. Tolerability and pharmacokinetics. J Child Adolesc Psychopharmacol. 2009;19:493\u20139.","journal-title":"J Child Adolesc Psychopharmacol."},{"key":"349_CR59","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1097\/01.chi.0000169012.81536.38","volume":"44","author":"CJ Kratochvil","year":"2005","unstructured":"Kratochvil CJ, Newcorn JH, Arnold LE, et al. Atomoxetine alone or combined with fluoxetine for treating ADHD with comorbid depressive or anxiety symptoms. J Am Acad Child Adolesc Psychiatry. 2005;44:915\u201324.","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"349_CR60","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1097\/01.chi.0000222788.34229.68","volume":"45","author":"CJ Kratochvil","year":"2006","unstructured":"Kratochvil CJ, Wilens TE, Greenhill LL, et al. Effects of long-term atomoxetine treatment for young children with attention-deficit\/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2006;45:919\u201327.","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"349_CR61","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1017\/S1047951111001211","volume":"22","author":"A Sert","year":"2012","unstructured":"Sert A, Gokcen C, Aypar E, et al. Effects of atomoxetine on cardiovascular functions and on QT dispersion in children with attention deficit hyperactivity disorder. Cardiol Young. 2012;22:158\u201361.","journal-title":"Cardiol Young"},{"key":"349_CR62","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1177\/1087054707306109","volume":"11","author":"TJ Spencer","year":"2008","unstructured":"Spencer TJ, Sallee FR, Gilbert DL, et al. Atomoxetine treatment of ADHD in children with comorbid Tourette syndrome. J Atten Disord. 2008;11:470\u201381.","journal-title":"J Atten Disord."},{"key":"349_CR63","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1080\/15563650600584311","volume":"44","author":"SD Stojanovski","year":"2006","unstructured":"Stojanovski SD, Robinson RF, Baker SD, et al. Children and adolescent exposures to atomoxetine hydrochloride reported to a poison control center. Clin Toxicol (Phila). 2006;44:243\u20137.","journal-title":"Clin Toxicol (Phila)."},{"key":"349_CR64","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1089\/cap.2008.0154","volume":"19","author":"M Takahashi","year":"2009","unstructured":"Takahashi M, Takita Y, Yamazaki K, et al. A randomized, double-blind, placebo-controlled study of atomoxetine in Japanese children and adolescents with attention-deficit\/hyperactivity disorder. J Child Adolesc Psychopharmacol. 2009;19:341\u201350.","journal-title":"J Child Adolesc Psychopharmacol."},{"key":"349_CR65","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.euroneuro.2007.06.002","volume":"18","author":"PT Trzepacz","year":"2008","unstructured":"Trzepacz PT, Williams DW, Feldman PD, et al. CYP2D6 metabolizer status and atomoxetine dosing in children and adolescents with ADHD. Eur Neuropsychopharmacol. 2008;18:79\u201386.","journal-title":"Eur Neuropsychopharmacol"},{"key":"349_CR66","doi-asserted-by":"crossref","first-page":"729","DOI":"10.2165\/00002018-200326100-00006","volume":"26","author":"JF Wernicke","year":"2003","unstructured":"Wernicke JF, Faries D, Girod D, et al. Cardiovascular effects of atomoxetine in children, adolescents, and adults. Drug Saf. 2003;26:729\u201340.","journal-title":"Drug Saf"},{"key":"349_CR67","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1097\/01.chi.0000190352.90946.0b","volume":"45","author":"TE Wilens","year":"2006","unstructured":"Wilens TE, Kratochvil C, Newcorn JH, et al. Do children and adolescents with ADHD respond differently to atomoxetine? J Am Acad Child Adolesc Psychiatry. 2006;45:149\u201357.","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"349_CR68","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.jpeds.2006.01.052","volume":"149","author":"TE Wilens","year":"2006","unstructured":"Wilens TE, Newcorn JH, Kratochvil CJ, et al. Long-term atomoxetine treatment in adolescents with attention-deficit\/hyperactivity disorder. J Pediatr. 2006;149:112\u20139.","journal-title":"J Pediatr"},{"key":"349_CR69","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1097\/01.chi.0000246056.83791.b6","volume":"46","author":"D Michelson","year":"2007","unstructured":"Michelson D, Read HA, Ruff DD, et al. CYP2D6 and clinical response to atomoxetine in children and adolescents with ADHD. J Am Acad Child Adolesc Psychiatry. 2007;46:242\u201351.","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"349_CR70","doi-asserted-by":"crossref","first-page":"e1701","DOI":"10.1542\/peds.2005-2999","volume":"118","author":"JH Newcorn","year":"2006","unstructured":"Newcorn JH, Michelson D, Kratochvil CJ, et al. Low-dose atomoxetine for maintenance treatment of attention-deficit\/hyperactivity disorder. Pediatrics. 2006;118:e1701\u20136.","journal-title":"Pediatrics"},{"key":"349_CR71","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/1753-2000-1-11","volume":"1","author":"S Prasad","year":"2007","unstructured":"Prasad S, Furr AJ, Zhang S, et al. Baseline values from the electrocardiograms of children and adolescents with ADHD. Child Adolesc Psychiatry Ment Health. 2007;1:11.","journal-title":"Child Adolesc Psychiatry Ment Health."},{"key":"349_CR72","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1016\/j.clinthera.2007.06.017","volume":"29","author":"H Quintana","year":"2007","unstructured":"Quintana H, Cherlin EA, Duesenberg DA, et al. Transition from methylphenidate or amphetamine to atomoxetine in children and adolescents with attention-deficit\/hyperactivity disorder-a preliminary tolerability and efficacy study. Clin Ther. 2007;29:1168\u201377.","journal-title":"Clin Ther"},{"key":"349_CR73","unstructured":"Gundogdu U, Benk F, Bahadir AT, et al. Treatment with atomoxetine: a case with Williams syndrome. Bulletin of Clinical Psychopharmacology. In: Conference: 5th international congress on psychopharmacology and international symposium on child and adolescent psychopharmacology: Turkey; 30 Oct\u20133 Nov 2013."},{"key":"349_CR74","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1007\/s40263-013-0104-8","volume":"27","author":"RW Dittmann","year":"2013","unstructured":"Dittmann RW, Cardo E, Nagy P, et al. Efficacy and safety of lisdexamfetamine dimesylate and atomoxetine in the treatment of attention-deficit\/hyperactivity disorder: a head-to-head, randomized, double-blind, phase IIIb study. CNS Drugs. 2013;27:1081\u201392.","journal-title":"CNS Drugs."},{"key":"349_CR75","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1007\/s13312-014-0445-5","volume":"51","author":"J Garg","year":"2014","unstructured":"Garg J, Arun P, Chavan BS. Comparative short term efficacy and tolerability of methylphenidate and atomoxetine in attention deficit hyperactivity disorder. Indian Pediatr. 2014;51:550\u20134.","journal-title":"Indian Pediatr"},{"issue":"12","key":"349_CR76","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1007\/s00431-013-2206-1","volume":"173","author":"H Yamaguchi","year":"2014","unstructured":"Yamaguchi H, Nagumo K, Nakashima T, et al. Life-threatening QT prolongation in a boy with attention-deficit\/hyperactivity disorder on atomoxetine. Eur J Pediatr. 2014;173(12):1631\u20134.","journal-title":"Eur J Pediatr"},{"key":"349_CR77","first-page":"S69","volume":"1","author":"A Bhagat","year":"2011","unstructured":"Bhagat A, Deshmukh V, Shah M, et al. Appetite and weight loss in children with attention deficit hyperactivity disorder taking atomoxetine. Indian J Psychiatry. 2011;1:S69\u201370.","journal-title":"Indian J Psychiatry."},{"key":"349_CR78","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.clinthera.2006.02.008","volume":"28","author":"J Biederman","year":"2006","unstructured":"Biederman J, Wigal SB, Spencer TJ, et al. A post hoc subgroup analysis of an 18-day randomized controlled trial comparing the tolerability and efficacy of mixed amphetamine salts extended release and atomoxetine in school-age girls with attention-deficit\/hyperactivity disorder. Clin Ther. 2006;28:280\u201393.","journal-title":"Clin Ther"},{"key":"349_CR79","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1016\/j.euroneuro.2009.07.008","volume":"19","author":"G Dell\u2019Agnello","year":"2009","unstructured":"Dell\u2019Agnello G, Maschietto D, Bravaccio C, et al. Atomoxetine hydrochloride in the treatment of children and adolescents with attention-deficit\/hyperactivity disorder and comorbid oppositional defiant disorder: a placebo-controlled Italian study. Eur Neuropsychopharmacol. 2009;19:822\u201334.","journal-title":"Eur Neuropsychopharmacol"},{"key":"349_CR80","first-page":"26","volume":"21","author":"TM Durell","year":"2009","unstructured":"Durell TM, Pumariega AJ, Rothe EM, et al. Effects of open-label atomoxetine on African\u2013American and Caucasian pediatric outpatients with attention-deficit\/hyperactivity disorder. Ann Clin Psychiatry. 2009;21:26\u201337.","journal-title":"Ann Clin Psychiatry"},{"key":"349_CR81","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1089\/104454601750284072","volume":"11","author":"CJ Kratochvil","year":"2001","unstructured":"Kratochvil CJ, Bohac D, Harrington M, et al. An open-label trial of tomoxetine in pediatric attention deficit hyperactivity disorder. J Child Adolesc Psychopharmacol. 2001;11:167\u201370.","journal-title":"J Child Adolesc Psychopharmacol."},{"key":"349_CR82","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/s00787-009-0042-7","volume":"19","author":"F Martenyi","year":"2010","unstructured":"Martenyi F, Zavadenko NN, Jarkova NB, et al. Atomoxetine in children and adolescents with attention-deficit\/hyperactivity disorder: a 6-week, randomized, placebo-controlled, double-blind trial in Russia. Eur Child Adolesc Psychiatry. 2010;19:57\u201366.","journal-title":"Eur Child Adolesc Psychiatry"},{"key":"349_CR83","doi-asserted-by":"crossref","first-page":"e74","DOI":"10.1542\/peds.2004-0624","volume":"116","author":"TJ Spencer","year":"2005","unstructured":"Spencer TJ, Newcorn JH, Kratochvil CJ, et al. Effects of atomoxetine on growth after 2-year treatment among pediatric patients with attention-deficit\/hyperactivity disorder. Pediatrics. 2005;116:e74\u201380.","journal-title":"Pediatrics"},{"key":"349_CR84","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1089\/cap.2006.0100","volume":"17","author":"TJ Spencer","year":"2007","unstructured":"Spencer TJ, Kratochvil CJ, Sangal RB, et al. Effects of atomoxetine on growth in children with attention-deficit\/hyperactivity disorder following up to five years of treatment. J Child Adolesc Psychopharmacol. 2007;17:689\u2013700.","journal-title":"J Child Adolesc Psychopharmacol."},{"issue":"Suppl 2","key":"349_CR85","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1185\/03007995.2011.599372","volume":"27","author":"PT Trzepacz","year":"2011","unstructured":"Trzepacz PT, Spencer TJ, Zhang S, et al. Effect of atomoxetine on Tanner stage sexual development in children and adolescents with attention deficit\/hyperactivity disorder: 18-month results from a double-blind, placebo-controlled trial. Curr Med Res Opin. 2011;27(Suppl 2):45\u201352.","journal-title":"Curr Med Res Opin"},{"key":"349_CR86","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1080\/00048670601057767","volume":"41","author":"Y Wang","year":"2007","unstructured":"Wang Y, Zheng Y, Du Y, et al. Atomoxetine versus methylphenidate in paediatric outpatients with attention deficit hyperactivity disorder: a randomized, double-blind comparison trial. Aust N Z J Psychiatry. 2007;41:222\u201330.","journal-title":"Aust N Z J Psychiatry"},{"key":"349_CR87","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1007\/s10578-010-0212-3","volume":"42","author":"O Yildiz","year":"2011","unstructured":"Yildiz O, Sismanlar SG, Memik NC, et al. Atomoxetine and methylphenidate treatment in children with ADHD: the efficacy, tolerability and effects on executive functions. Child Psychiatry Hum Dev. 2011;42:257\u201369.","journal-title":"Child Psychiatry Hum Dev"},{"key":"349_CR88","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1089\/cap.2006.16.599","volume":"16","author":"DJ Posey","year":"2006","unstructured":"Posey DJ, Wiegand RE, Wilkerson J, et al. Open-label atomoxetine for attention-deficit\/hyperactivity disorder symptoms associated with high-functioning pervasive developmental disorders. J Child Adolesc Psychopharmacol. 2006;16:599\u2013610.","journal-title":"J Child Adolesc Psychopharmacol."},{"key":"349_CR89","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1159\/000348792","volume":"6","author":"W Pott","year":"2013","unstructured":"Pott W, Albayrak O, Hinney A, et al. Successful treatment with atomoxetine of an adolescent boy with attention deficit\/hyperactivity disorder, extreme obesity, and reduced melanocortin 4 receptor function. Obes Facts. 2013;6:109\u201315.","journal-title":"Obes Facts."},{"issue":"10","key":"349_CR90","first-page":"976","volume":"32","author":"M Davies","year":"2009","unstructured":"Davies M, Cornelius V, Fogg C, et al. A study to examine events of suicidal ideation in patients prescribed atomoxetine in England; results of an interim modified prescription event monitoring study. Drug Saf. 2009;32(10):976.","journal-title":"Drug Saf"},{"issue":"Suppl 1","key":"349_CR91","first-page":"175","volume":"22","author":"S Linden","year":"2013","unstructured":"Linden S, Bussing R, Gerhard T, et al. Risk of suicide and suicide attempt associated with atomoxetine compared to central nervous system stimulant treatment. Pharmacoepidemiol Drug Saf. 2013;22(Suppl 1):175\u20136.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"349_CR92","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.1056\/NEJMoa1110212","volume":"365","author":"WO Cooper","year":"2011","unstructured":"Cooper WO, Habel LA, Sox CM, et al. ADHD drugs and serious cardiovascular events in children and young adults. N Engl J Med. 2011;365:1896\u2013904.","journal-title":"N Engl J Med"},{"issue":"6","key":"349_CR93","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1542\/peds.2010-3371","volume":"127","author":"H Schelleman","year":"2011","unstructured":"Schelleman H, Bilker WB, Strom BL, et al. Cardiovascular events and death in children exposed and unexposed to ADHD agents. Pediatrics. 2011;127(6):1102\u201310.","journal-title":"Pediatrics"},{"key":"349_CR94","unstructured":"Heads of Medicines Agencies (HMA). Medicines approval system. http:\/\/www.hma.eu\/medicinesapprovalsystem.html . Accessed 2 Dec 2015."},{"key":"349_CR95","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1177\/0269881113478475","volume":"28","author":"CJ Bushe","year":"2014","unstructured":"Bushe CJ, Savill NC. Systematic review of atomoxetine data in childhood and adolescent attention-deficit hyperactivity disorder 2009\u20132011: focus on clinical efficacy and safety. J Psychopharmacol. 2014;28:204\u201311.","journal-title":"J Psychopharmacol."},{"key":"349_CR96","unstructured":"Duff G. Strattera (atomoxetine)\u2014conclusions of a risk:benefit review. MHRA. 2006. http:\/\/webarchive.nationalarchives.gov.uk\/20141205150130\/ . http:\/\/www.mhra.gov.uk\/Safetyinformation\/Safetywarningsalertsandrecalls\/Safetywarningsandmessagesformedicines\/CON2023222 . Accessed 9 July 2015."},{"key":"349_CR97","unstructured":"MHRA public assessment report. Atomoxetine: a review of the effects on heart rate and blood pressure. 2012. http:\/\/www.mhra.gov.uk\/home\/groups\/s-par\/documents\/websiteresources\/con152778.pdf . Accessed 9 July 2015."},{"key":"349_CR98","unstructured":"MHRA public assessment report. Strattera 4\u00a0mg\/mL oral solution (atomoxetine hydrochloride). 2014. http:\/\/www.mhra.gov.uk\/home\/groups\/par\/documents\/websiteresources\/con493430.pdf . Accessed 9 July 2015."},{"key":"349_CR99","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1586\/14737175.2014.904748","volume":"14","author":"S Cortese","year":"2014","unstructured":"Cortese S, Castellanos FX. The relationship between ADHD and obesity: implications for therapy. Expert Rev Neurother. 2014;14:473\u20139.","journal-title":"Expert Rev Neurother"},{"key":"349_CR100","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1186\/1471-244X-13-286","volume":"13","author":"S Cortese","year":"2013","unstructured":"Cortese S, Comencini E, Vincenzi B, et al. Attention-deficit\/hyperactivity disorder and impairment in executive functions: a barrier to weight loss in individuals with obesity? BMC Psychiatry. 2013;13:286.","journal-title":"BMC Psychiatry."},{"key":"349_CR101","doi-asserted-by":"publisher","DOI":"10.1111\/sjop.12219","author":"K Kompus","year":"2015","unstructured":"Kompus K, L\u00f8berg EM, Posserud MB, Lundervold AJ. Prevalence of auditory hallucinations in Norwegian adolescents: Results from a population-based study. Scand J Psychol. Epub. 2015;. doi: 10.1111\/sjop.12219 .","journal-title":"Scand J Psychol. Epub"},{"key":"349_CR102","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1192\/bjp.bp.109.065953","volume":"196","author":"AA Bartels-Velthuis","year":"2010","unstructured":"Bartels-Velthuis AA, Jenner JA, van de Willige G, et al. Prevalence and correlates of auditory vocal hallucinations in middle childhood. Br J Psychiatry. 2010;196:41\u20136.","journal-title":"Br J Psychiatry"},{"key":"349_CR103","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1192\/bjp.bp.110.086918","volume":"199","author":"AA Bartels-Velthuis","year":"2011","unstructured":"Bartels-Velthuis AA, van de Willige G, Jenner JA, et al. Course of auditory vocal hallucinations in childhood: 5-year follow-up study. Br J Psychiatry. 2011;199:296\u2013302.","journal-title":"Br J Psychiatry"},{"key":"349_CR104","doi-asserted-by":"publisher","DOI":"10.1002\/eat.22404","author":"SP Reinblatt","year":"2015","unstructured":"Reinblatt SP, Mahone EM, Tanofsky-Kraff M, et al. Pediatric loss of control eating syndrome: association with attention-deficit\/hyperactivity disorder and impulsivity. Int J Eat Disord. 2015. doi: 10.1002\/eat.22404 .","journal-title":"Int J Eat Disord"},{"key":"349_CR105","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1001\/archgenpsychiatry.2010.127","volume":"67","author":"A Chronis-Tuscano","year":"2010","unstructured":"Chronis-Tuscano A, Molina BS, Pelham WE, et al. Very early predictors of adolescent depression and suicide attempts in children with attention-deficit\/hyperactivity disorder. Arch Gen Psychiatry. 2010;67:1044\u201351.","journal-title":"Arch Gen Psychiatry"},{"key":"349_CR106","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1185\/030079908X253627","volume":"24","author":"RJ Bakken","year":"2008","unstructured":"Bakken RJ, Paczkowski M, Kramer HP, et al. Effects of atomoxetine on attention-deficit\/hyperactivity disorder in clinical pediatric treatment settings: a naturalistic study. Curr Med Res Opin. 2008;24:449\u201360.","journal-title":"Curr Med Res Opin"},{"key":"349_CR107","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1517\/14740338.2015.1011620","volume":"14","author":"PG Hammerness","year":"2015","unstructured":"Hammerness PG, Karampahtsis C, Babalola R, et al. Attention-deficit\/hyperactivity disorder treatment: what are the long-term cardiovascular risks? Expert Opin Drug Saf. 2015;14:543\u201351.","journal-title":"Expert Opin Drug Saf."},{"key":"349_CR108","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.pediatrneurol.2010.01.005","volume":"42","author":"SM Davis","year":"2010","unstructured":"Davis SM, Katusic SK, Barbaresi WJ, et al. Epilepsy in children with attention-deficit\/hyperactivity disorder. Pediatr Neurol. 2010;42:325\u201330.","journal-title":"Pediatr Neurol"},{"key":"349_CR109","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1001\/archpsyc.61.7.731","volume":"61","author":"DC Hesdorffer","year":"2004","unstructured":"Hesdorffer DC, Ludvigsson P, Olafsson E, et al. ADHD as a risk factor for incident unprovoked seizures and epilepsy in children. Arch Gen Psychiatry. 2004;61:731\u20136.","journal-title":"Arch Gen Psychiatry"},{"key":"349_CR110","doi-asserted-by":"crossref","first-page":"e57926","DOI":"10.1371\/journal.pone.0057926","volume":"8","author":"IC Chou","year":"2013","unstructured":"Chou IC, Chang YT, Chin ZN, et al. Correlation between epilepsy and attention deficit hyperactivity disorder: a population-based cohort study. PLoS ONE. 2013;8:e57926.","journal-title":"PLoS ONE"},{"key":"349_CR111","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/j.seizure.2013.04.021","volume":"22","author":"D Socanski","year":"2013","unstructured":"Socanski D, Aurlien D, Herigstad A, et al. Epilepsy in a large cohort of children diagnosed with attention deficit\/hyperactivity disorders (ADHD). Seizure. 2013;22:651\u20135.","journal-title":"Seizure."},{"key":"349_CR112","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/1753-2000-8-15","volume":"8","author":"E Ercan","year":"2014","unstructured":"Ercan E, Ercan ES, At\u0131lgan H, et al. Predicting aggression in children with ADHD. Child Adolesc Psychiatry Ment Health. 2014;8:15.","journal-title":"Child Adolesc Psychiatry Ment Health."},{"key":"349_CR113","doi-asserted-by":"publisher","unstructured":"Savill N, Bushe CJ. A systematic review of the safety information contained within the Summaries of Product Characteristics of medications licensed in the United Kingdom for Attention Deficit Hyperactivity Disorder. How does the safety prescribing advice compare with national guidance? Child Adolesc Psychiatry Ment Health. 2012;6(1):2. doi: 10.1186\/1753-2000-6-2 .","DOI":"10.1186\/1753-2000-6-2"},{"key":"349_CR114","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.ijlp.2009.04.006","volume":"32","author":"W Retz","year":"2009","unstructured":"Retz W, R\u00f6sler M. The relation of ADHD and violent aggression: What can we learn from epidemiological and genetic studies? Int J Law Psychiatry. 2009;32:235\u201343.","journal-title":"Int J Law Psychiatry"},{"key":"349_CR115","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1111\/j.1469-7610.2009.02107.x","volume":"50","author":"KJ Lifford","year":"2009","unstructured":"Lifford KJ, Harold GT, Thapar A. Parent-child hostility and child ADHD symptoms: a genetically sensitive and longitudinal analysis. J Child Psychol Psychiatry. 2009;50:1468\u201376.","journal-title":"J Child Psychol Psychiatry"},{"issue":"2","key":"349_CR116","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1176\/appi.ajp.2011.10111705","volume":"169","author":"B Vitiello","year":"2012","unstructured":"Vitiello B, Elliott GR, Swanson JM, et al. Blood pressure and heart rate over 10\u00a0years in the multimodal treatment study of children with ADHD. Am J Psychiatry. 2012;169(2):167\u201377.","journal-title":"Am J Psychiatry"},{"issue":"8","key":"349_CR117","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1097\/chi.0b013e3180686d7e","volume":"46","author":"JM Swanson","year":"2007","unstructured":"Swanson JM, Elliott GR, Greenhill LL, et al. Effects of stimulant medication on growth rates across 3\u00a0years in the MTA follow-up. J Am Acad Child Adolesc Psychiatry. 2007;46(8):1015\u201327.","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"12","key":"349_CR118","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.4088\/JCP.12m07991","volume":"74","author":"LA Wietecha","year":"2013","unstructured":"Wietecha LA, Ruff DD, Allen AJ, et al. Atomoxetine tolerability in pediatric and adult patients receiving different dosing strategies. J Clin Psychiatry. 2013;74(12):1217\u201323.","journal-title":"J Clin Psychiatry"}],"container-title":["CNS Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-016-0349-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40263-016-0349-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-016-0349-0","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,24]],"date-time":"2017-06-24T12:11:51Z","timestamp":1498306311000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40263-016-0349-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,6,11]]},"references-count":118,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2016,7]]}},"alternative-id":["349"],"URL":"https:\/\/doi.org\/10.1007\/s40263-016-0349-0","relation":{},"ISSN":["1172-7047","1179-1934"],"issn-type":[{"value":"1172-7047","type":"print"},{"value":"1179-1934","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,6,11]]}}}